Study for the safety and effectiveness of percutaneous cryoablation of thoracic tumor

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027872

Enrollment

Unknown

Registered

2019-12-01

Start date

2019-12-01

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

China:percutaneous cryoablation of thoracic tumor

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Outpatient or inpatient patients aged 18-85 years; 2. Patients with cardiopulmonary function resistant to cryoablation; 3. 2018 cryoablation for lung tumors that are within the scope of indications as stipulated by the consensus of lung oncology experts and those that have failed drug therapy; 4. Good compliance and regular follow-up, including necessary tests and examinations.

Exclusion criteria

Exclusion criteria: 1. Freezing ablation cannot be tolerated in patients with severe organic disease. 2. Patients with Various hemorrhagic diseases. 3. Acute infectious diseases. 4. Fever. 5. Pregnancy. 6. Previous history of other systemic malignancies or organ transplantation. 7. Have a history of drug abuse or mental illness. 8. Previous pneumonectomy.

Design outcomes

Primary

Measure	Time frame
Tumor diameter;	—

Countries

China

Contacts

Public ContactLihong Fan

The Tenth People's Hospital affiliated to Tongji University

fanlih@aliyun.com+86 18001763288

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026